Relay Therapeutics Inc (NASDAQ: RLAY) closed the day trading at $7.95 down -2.69% from the previous closing price of $8.17. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 3750956 shares were traded.
Ratios:
For a better understanding of RLAY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.44 and its Current Ratio is at 25.44. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 19, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $29.
On April 13, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $29.Raymond James initiated its Outperform rating on April 13, 2023, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 29 ’24 when Bergstrom Donald A sold 3,178 shares for $9.64 per share. The transaction valued at 30,636 led to the insider holds 530,878 shares of the business.
Catinazzo Thomas sold 2,005 shares of RLAY for $19,328 on Jan 29 ’24. The Chief Financial Officer now owns 341,846 shares after completing the transaction at $9.64 per share. On Jan 29 ’24, another insider, Adams Brian, who serves as the Chief Legal Officer of the company, sold 1,929 shares for $9.64 each. As a result, the insider received 18,596 and left with 327,738 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1.04B and an Enterprise Value of 346.25M. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.82 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 13.55 whereas that against EBITDA is -0.93.
Stock Price History:
Over the past 52 weeks, RLAY has reached a high of $19.23, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is 10.02, while the 200-Day Moving Average is calculated to be 9.98.
Shares Statistics:
Over the past 3-months, RLAY traded about 1.02M shares per day on average, while over the past 10 days, RLAY traded about 1.18M shares per day. A total of 127.46M shares are outstanding, with a floating share count of 92.20M. Insiders hold about 29.71% of the company’s shares, while institutions hold 71.64% stake in the company. Shares short for RLAY as of Feb 29, 2024 were 11M with a Short Ratio of 10.80, compared to 9.45M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.38% and a Short% of Float of 10.79%.
Earnings Estimates
Current recommendations for the stock of the company come from 8 analysts. On average, analysts expect EPS of -$0.71 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.81, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.68 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.59 and -$3.33 for the fiscal current year, implying an average EPS of -$2.93. EPS for the following year is -$2.8, with 9 analysts recommending between -$2.31 and -$3.11.
